OncoSolid™ Pancreatic Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Brief Description

Pancreatic cancer is one of the highly malignant cancers with a poor prognosis and nearly 3% of five-year survival rate. Our knowledge about pathogenesis, early diagnosis, and effective treatment is rare for pancreatic cancer. CAR-T therapies have got exciting outcomes in Leukemia treatment and are adapted for various advanced solid tumors. Cancer organoids that recapitulate the pathological and genetic characteristics of tumors can be adapted to facilitate the research on tumor profiling and evaluation of the functions of immunotherapies.

Creative Biolabs provides a group of thoroughly characterized pancreatic cancer organoid models to test the efficacy of specific CAR-T cells for cancer treatment.

Fig.1 Pancreatic cancer organoid serves as a functional preclinical research model. (Shi, et al., 2022)

Key Features of The Pancreatic Cancer Organoid Models

Pancreatic organoids are incorporated with stromal cells and immune components.
Pancreatic cancer organoids are established from tumors originating from patients and genetically engineered mice.
Establish cancer organoids in no more than two weeks.
Cancer organoids can be established to recapitulate high intratumoral pressure in PDAC.

Workflow for Lung Cancer Organoid Generation

Fig.2 Our establishing workflow of pancreatic organoid models. (Creative Biolabs)

Subtypes of Pancreatic Cancer Organoid Models

Pancreatic Ductal Adenocarcinoma (PDAC) organoid models
Intraductal Papillary Mucinous Neoplasms (IPMNs) organoid models
Acinar Cell Carcinoma (ACC) organoid models
Pancreatic Neuroendocrine Neoplasms (NENs) organoid models

Characterization of the Established Organoids

Histology

H&E staining

Alcian blue staining

IHC (Immunohistochemistry)

The histological and genomic characteristics of the established organoids and the initial tumors are measured, using various advanced tumor profiling technologies.

Types of Pancreatic Cancer and Corresponding Organoid Features

Type of Cancer Organoid	Morphology	Tumor cell identification
PDAC organoid models	Glandular tubular structures	Ductal cell marker (CK19)
IPMNs organoid models	Data under update	Identification of Mucinous neoplasm by alcian blue staining
ACC organoid models	Data under update	α1-Antichymotrypsin (α1-ACT) Bcl-10
NENs organoid models	NENs-specific Islet morphology	Chromogranin-A (CHGA) Synaptophysin (SYP)

Genomics Analysis

Sequencing approaches

Whole-genome sequencing (WGS)
RNA sequencing
ATAC-seq

sample

Primary tumor tissues
Tumor organoids
Xenografts, and normal tissues

Gene mutational spectrum

Exonic mutations
Intronic mutations
Noncoding mutations
Gene mutation induced regulatory networks
Copy number variants

Data Analysis

Sequencing data compared to databases
TCGA dataset
COSMIC database
OncoKB database

Our Pancreatic Cancer-Related CAR-T Products and Services

Creative Biolabs provides CAR-T products targeted to the following cancer associated antigens and can be applied to pancreatic cancer organoids treatment in vitro.

Target Antigen	Target Description	Products
HER2	HER2 is amplified in multiple cancers, including breast, gastric, and pancreatic, and is a therapeutic target for cancer treatment.	Anti-HER2 CAR-T
PSCA	PSCA expression is increased in human pancreatic cancer than in normal tissues. CAR-NK directed to PSCA displayed repression effects on PSCA+ pancreatic cancer.	Anti-PSCA CAR-T
MUC1	Expression of MUC1 is elevated in nearly 90% of pancreatic cancer patients and is a valuable biomarker for diagnosis and targeted treatment.	Anti-MUC1 CAR-T
EpCAM	Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein. The high expression of EpCAM is associated with the development and progression of tumors.	Anti-EpCAM CAR-T
CEA	Carcinoembryonic antigen (CEA) is a robust biomarker that can be used to predict advanced pancreatic ductal adenocarcinoma (PDAC).	Anti-CEA CAR-T
Avb6	Avb6 protein is expressed in approximately 80% of pancreatic cancer and is associated with the growth and metastasis of tumor cells.	Anti-Avb6 CAR-T

Products	One-Stop CAR-T Therapy Development Services
CAR IVT Plasmid-mRNA-LNP Products CAR Vector Products CAR Cells CAR Jurkat Cell Products CAR Animal Cells CAR Lentivirus Packaging Kit Kits for CARs/TCRs Development	Biomarker Identification & Selection scFv Generation CAR Design & Construction CAR-T Gene Packaging & Delivery Replication-Competent Virus Testing Service CAR Cell In Vitro Assay Service CAR-T Preclinical In Vivo Assay IND Development for CAR-T Cell Therapy GMP Production for CAR-T Products CAR Clinical Trials

Published Data

Pancreatic Cancer Organoids Derived from Patient Tumor Tissue
Pancreatic tumor organoids established from tumors of PDAC, IPMN, NEN, and ACC showed similar phenotypic and genomic features with the original tissue.
Representative Results	Fig.3 Histological and immunohistological patterns of cancer organoids and tumor tissues. (Shi, et al., 2022)
	Fig.4 Whole genome analysis of patient-derived pancreatic organoids. (Shi, et al., 2022)

Contact Us

Creative Biolabs provides well-established cancer organoid models for the evaluation of CAR-T cell functions in vitro to help clients develop the safest and most efficient therapies. Please contact us and get more detailed information.

Reference

Shi, X.; et al. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nature communications. 2022 13(1): 2169.